on alteration of restriction fragment length polymorphisms in ALL cells, which could be interpreted as being due to acquired mutations. We therefore sought mitochondrial mutations in 22 patients with acute myeloid leukaemia (AML) (11 males, 11 females, ages 16-69) and 26 patients with ALL (14 males, 12 females, 23 children, three adults). In all, 15 of the ALL patients were specifically selected because they had relapsed. All patients were studied by sequencing the mitochondrial D loop from nucleotides 16111-190 and in 37 patients; the same region was also studied by denaturing gradient gel electrophoresis (DGGE). Mutations were found at diagnosis by sequencing in eight of the 22 patients (36%) with AML and 15 of the 26 patients (58%) with ALL. The difference in frequency between AML and ALL was not significant (P ¼ 0.09, Fisher's exact test). Aberrant bands resulting from mutation were detected by DGGE with a sensitivity of 93% and a specificity of 98%.
When mutations were detected in a patient, they were usually multiple. For the AML patients in whom mutations were detected, the median number of point mutations was 6.0 with a range of 1-14 and for the ALL patients in whom mutations were detected the median was 4.5 with a range of 1-10. If the mutations observed in leukaemic cells were the result of random occurrence of mutations in normal cells, followed by the development of leukaemia in an already mutated cell, then the distribution of mutations/patient would follow a Poisson distribution, the characteristics of which could be inferred from Results for one patient showing DGGE results for one segment, sequence differences with base numbers for that segment and a hypothetical evolutionary pathway of mutation and selection. In the DGGE the relapse band can be faintly seen in the remission material.
Figure 2
Number of mutations at each base position along the D loop.
Table 1
Frequencies of certain mutations of interest The total number of mutations observed was 52 in AML and 81 in ALL. The first four columns show the commonest mutations observed; the last column shows the fequency of G-T (or C-A on the other strand), which is a signature mutation of oxidative damage. Significance values were determined by calculating w 2 with Yates correction.
the proportion of patients not showing a mutation. Based on the observation that 25 of the 48 patients studied were free of mutations, the mean number of mutations/patient would have been expected to be 0.65 and the total number of mutations in the 48 patients would have been expected to be 33. Since 116 mutations were actually detected at diagnosis, the results suggest that at least 73% of detected mutations occurred during growth of the leukaemic clone. The bimodal distribution in the number of mutations observed in both the AML and ALL patients suggests either an individual-related or a leukaemia-related mechanism which leads to increased mutagenesis, but which is present only in some individuals or some leukaemias. Polymorphism or mutations in DNA processing or repair genes would be obvious possibilities. The number of mitochondrial mutations and their spectrum at diagnosis and relapse provide information on clonal evolution in leukaemia. The large number of mutations at diagnosis in many patients suggests that a large number of clones was present at diagnosis at that time, at least in those patients. There were nine patients who were sequenced at diagnosis, in whom mutations were detected at that time, and who were also sequenced at relapse. In four of them, the same mutations were detected at relapse as at diagnosis. In one patient, there were six mutations in the relapse clone, which had not been detected in the diagnosis clone; the relapse clone must have branched off from the diagnosis clone, but the time at which this occurred cannot be determined. However, in four of the nine patients, there were mutations present in the diagnosis clone which were not present in the relapse clone, indicating that the two clones had diverged at some time prior to diagnosis. DGGE of the remission sample had been performed in three of these four patients and showed that the relapse band could also be detected, albeit faintly, in two of them. The results in these four patients therefore suggest a process of clonal evolution which led to at least two principal clones being present at diagnosis, one of which predominated but which was relatively sensitive to chemotherapy, the other of which was smaller in size but resistant to chemotherapy and responsible for relapse. In Figure 1 , detailed results for one of these patients, together with a hypothesised pathway depicting clonal evolution, are shown. In this patient, inspection of the phylogenetic tree for this segment indicates that at least five subclones were present at diagnosis. From consideration of the mutation spectra and DGGE bands present at remission, we calculated that the number of leukaemic subclones present at diagnosis in the above nine patients was 2, 4, 5, 6, 7, 9, 10, 11 and 14. Evidence from study of gene rearrangements also supports the concept that in ALL multiple clones are present at diagnosis 3, 4 and that they may differ in chemosensitivity. 5, 6 de Haas et al 6 noted that the relapse clone could be detected at diagnosis in two of three relapsed patients and we have noted the same in four of six relapsed patients. 7 Both the location and the nature of the mitochondrial mutations were not random. The location of mutations along the D loop is shown in Figure 2 . Mutations tended to occur at hot-spots rather than being distributed according to Poisson statistics (>w 2 2 ¼ 80.0, Po0.001). Several hot-spots were at sites of poly C tracts, but there was no single-sequence motif which seemed to be associated with mutations. All mutations were point mutations except for one instance of a T deletion. A total of 133 mutations was detected at diagnosis or relapse and the frequency of occurrence of selected mutations is shown in Table 1 . For the region sequenced, the total GC content was 48.1% and the AT content was 51.9%. For the coding strand, the frequency of each base was: C, 32%; T, 23%; G, 16%; A, 29%.
As shown in Figure 2 , there was a highly significant increase in C-T and T-C transitions, but only minor nonsignificant increases in G-A and A-G. The findings suggest strand bias in mutations either towards pyrimidine transitions on the coding strand or purine transitions on the noncoding strand. There was a highly significant decrease in G-T and C-A transversions and no tandem mutations were observed.
Mitochondrial mutations are often hypothesised as being due to DNA damage by oxidising radicals. The common 'signature' mutations following oxidative damage and repair of DNA are C-T, CC-TT and G-T, and they are believed to result from mispairing of oxidised bases during replication. 8 Although our data showed a high frequency of C-T, the high frequency of T-C and low frequency of G-T (or C-A, which corresponds to G-T on the noncoding strand) argue that factors other than oxidative damage are likely to be important aetiological factors in the mutations in leukaemia. Khrapko et al 9 studied mitochondrial DNA from normal and carcinoma samples, found predominantly A-G and G-A mutations and hypothesised that they arose from polymerase gamma errors during replication. We likewise observed a high frequency of transitions on the coding strand, which however involved pyrimidines rather than purines. Deamination of cytosine may be an important mechanism for hypermutation in activated lymphocytes 10 and a speculative explanation for our findings is that the excess of C-T and T-C mutations may reflect overexpression of cytosine and adenine deaminases in leukaemia.
The relationship between the presence of a mitochondrial mutation and the leukaemic process is speculative. The mutation may have been present in the cell of origin of the leukaemia or it may have originated during growth of the leukaemic clone. In terms of its effect on progression of the leukaemia, the mutation may have been neutral in effect or it may have provided a selective advantage. These various possibilities are not mutually exclusive and their importance may differ for different mutations. Our findings on the frequency distribution of mitochondrial mutations in different patients and on the differences in mutation spectra between diagnosis and relapse are direct evidence that the majority of mitochondrial mutations in leukaemia occur during growth of the leukaemic clone. It is conceivable that a mutation in a mitochondrial genome might result in a selective growth or survival advantage for the cell bearing that mutation. Mitochondria play a role in apoptosis and a mutation in a gene coding for a mitochondrial protein might conceivably have an antiapoptotic effect, thus favouring survival of the cell containing the mutated mitochondrion and also favouring genetic drift and during genetic drift in the direction of mitochondrial homeoplasmy. However, this possibility seems unlikely for mutations in the D loop as this region is non-coding and mutations in it would be expected to have little or no phenotypic effect. We suggest that the most common situation is that a clone defined by a mitochondrial mutation contains within it a subclone that carries elsewhere in its genome another mutation that does provide a selective advantage; that the mitochondria within an ancestral cell of the subclone have become homeoplasmic owing to random genetic drift; and that the subclone becomes dominant within the clone owing to the selective advantage of this other mutation. 
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TO THE EDITOR
Based on murine studies that demonstrate the induction of anti-AML immunity following vaccination with autologous leukaemia cells engineered to express immunomodulatory cytokines and costimulatory molecules, and on promising early reports of this approach being tested in other human malignancies, we and others have commenced human trials of autologous cellular vaccination in primary and MDS-related AML. We have explored the use of adenoviral vectors for producing such vaccines.
Gene transfer by adenoviral vectors of the most commonly used serotypes -types 2 and 5 -is known to comprise a sequential, multistep process. 1 Blocking studies with neutralizing antibodies and peptides have shown that the first step -viral attachment -is mediated by the binding of the adenoviral fibre protein to the coxsackievirus and adenovirus receptor (CAR) (or to other cell surface molecules in the case of vectors bearing modified fibre proteins), while the subsequent steps -viral internalization and intracellular viral DNA release by endosome rupture -require the interaction of a distinct adenoviral protein, the penton base, with a v integrins. 1 As the overall efficiency of adenoviral gene transfer is dependent on each of these sequential steps, adenoviral infection can be impaired by both low-level CAR or a v integrin expression.
Normal primitive haematopoietic progenitors reportedly do not express adenoviral receptors and as a result are believed to be infected inefficiently by adenoviral vectors. 2 Indeed, this reported relative resistance of CD34 þ haematopoietic precursors to adenoviral infection, compared with the ease with which various carcinoma cells can be infected, has been proposed as the basis for a potential adenovirus-mediated stem cell autograft purging strategy for patients with carcinoma undergoing stem cell transplantation. Although the cell surface expression of CAR and of the a v integrins by AML blasts has not been defined, by analogy with their normal CD34 þ counterparts, these cells have similarly been presumed to be nonpermissive for adenoviral gene transfer strategies.
Notably, however, we and others have observed that AML cells can indeed be infected readily with adenoviral vectors, albeit with markedly variable efficiency (reported transduction efficiencies range from 0 to 83% 3 among investigators, and demonstrate marked intrastudy variability as well 3 ). The basis for this variability has not been defined. We reasoned that the susceptibility of AML blasts to adenoviral gene transfer might reflect variable expression of the molecules known to govern adenoviral attachment (CAR), internalization (integrins a v b 3 and a v b 5 ) and intracellular viral DNA release (integrin a v b 5 ). 1 In cells expressing high levels of these molecules, such as HeLa cells, adenovirus-mediated gene transfer is very efficient, and requires only a low virus/cell ratio (MOI) and a short viral incubation time. In contrast, in cells with absent or weak expression, such as lymphocytes, adenoviral infection is inefficient and requires a high MOI and a long viral incubation time (and the use of cationic polymer or lipid transfection adjuvants, or the addition of haematopoietic growth factors, in some cases 3 ). We therefore assessed the cell surface expression of CAR and of the integrins a v b 3 and a v b 5 on AML cells from 38 patients, 16 of whom met WHO criteria for AML with prior MDS. CAR and integrins a v b 3 and a v b 5 expression were determined flow cytometrically using a CD45/side scatter/dead cell exclusion gating strategy, and mAbs reactive specifically with human CAR (clone RmcB), integrin a v b 3 (clone LM609, gift from D Cheresh), integrin a v b 5
